Open-label trial of imatinib in combination with vinorelbine for patients with advanced breast carcinoma: ICON.
Phase of Trial: Phase IV
Latest Information Update: 09 Feb 2017
At a glance
- Drugs Imatinib (Primary) ; Vinorelbine (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Acronyms ICON; INV181
- Sponsors Novartis; Novartis Pharmaceuticals
- 10 Dec 2012 To date, 33 patients have been enrolled in the study. Recruitment for dose groups 1-3 is complete.
- 01 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 30 Apr 2012 Planned end date changed from 1 Dec 2010 to 1 Jun 2012 as reported by ClinicalTrials.gov.